Renovorx launches multi-center post-marketing registry study to evaluate cancer treatment delivered by renovocath® device to solid tumors

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath, a patented, fda-cleared drug-delivery device, today announced the launch of the panther post-marketing registry study (nct06805461). the initiation of this study demonstrates renovorx's commitment to innovation and renovocath's current and future potential. the study will serve as a critical.
RNXT Ratings Summary
RNXT Quant Ranking